JP6545254B2 - リン含有フェナントロリン誘導体及びその調製方法と応用 - Google Patents

リン含有フェナントロリン誘導体及びその調製方法と応用 Download PDF

Info

Publication number
JP6545254B2
JP6545254B2 JP2017504230A JP2017504230A JP6545254B2 JP 6545254 B2 JP6545254 B2 JP 6545254B2 JP 2017504230 A JP2017504230 A JP 2017504230A JP 2017504230 A JP2017504230 A JP 2017504230A JP 6545254 B2 JP6545254 B2 JP 6545254B2
Authority
JP
Japan
Prior art keywords
compound
formula
acid
preparation
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017504230A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017513934A5 (enExample
JP2017513934A (ja
Inventor
朱岳
▲リョウ▼玉珍
▲張▼莉
柏旭
Original Assignee
シアメン ベリル セラピューティクス インコーポレイテッド
シアメン ベリル セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シアメン ベリル セラピューティクス インコーポレイテッド, シアメン ベリル セラピューティクス インコーポレイテッド filed Critical シアメン ベリル セラピューティクス インコーポレイテッド
Publication of JP2017513934A publication Critical patent/JP2017513934A/ja
Publication of JP2017513934A5 publication Critical patent/JP2017513934A5/ja
Application granted granted Critical
Publication of JP6545254B2 publication Critical patent/JP6545254B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/657163—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom
    • C07F9/657181—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms the ring phosphorus atom being bound to at least one carbon atom the ring phosphorus atom and, at least, one ring oxygen atom being part of a (thio)phosphonic acid derivative

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017504230A 2014-04-10 2015-04-10 リン含有フェナントロリン誘導体及びその調製方法と応用 Active JP6545254B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410142608.8A CN104974187A (zh) 2014-04-10 2014-04-10 菲罗啉类衍生物及其制备方法和应用
CN201410142608.8 2014-04-10
PCT/CN2015/076273 WO2015154716A1 (zh) 2014-04-10 2015-04-10 菲罗啉膦酸类衍生物及其制备方法和应用

Publications (3)

Publication Number Publication Date
JP2017513934A JP2017513934A (ja) 2017-06-01
JP2017513934A5 JP2017513934A5 (enExample) 2018-04-26
JP6545254B2 true JP6545254B2 (ja) 2019-07-17

Family

ID=54271195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017504230A Active JP6545254B2 (ja) 2014-04-10 2015-04-10 リン含有フェナントロリン誘導体及びその調製方法と応用

Country Status (9)

Country Link
US (1) US10072035B2 (enExample)
EP (1) EP3130593B1 (enExample)
JP (1) JP6545254B2 (enExample)
KR (1) KR102369908B1 (enExample)
CN (2) CN104974187A (enExample)
CA (1) CA2944805C (enExample)
EA (1) EA030709B1 (enExample)
SG (1) SG11201608422VA (enExample)
WO (1) WO2015154716A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108863797B (zh) * 2018-07-02 2021-01-15 吉首大学 一类3-(取代/非取代苯基)-3-羟基丙酰氧肟酸的制备方法
CN114958927A (zh) * 2021-02-22 2022-08-30 尚科生物医药（上海）有限公司 一种制备(s)-1-(3-氯苯基)-1,3-丙二醇的方法
CN113072585B (zh) * 2021-04-02 2023-11-10 厦门市博瑞来医药科技有限公司 手性芳基膦酸环二酯及其衍生物的制备

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3524846A (en) 1967-06-02 1970-08-18 Syntex Corp Process for the didealkylation of phosphonate esters
US6011021A (en) * 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
AU754607B2 (en) * 1997-10-24 2002-11-21 Fibrogen, Inc. Phenanthroline derivatives
US5916898A (en) * 1997-10-24 1999-06-29 Zeneca Limited Phenanthroline derivatives
BR0306785A (pt) * 2002-01-07 2004-11-09 Eisai Co Ltd Deazapurinas e seus usos
CA2594777A1 (en) * 2005-01-19 2006-07-27 Biolipox Ab Indoles useful in the treatment of inflamation
JP5362999B2 (ja) * 2008-01-30 2013-12-11 九州電力株式会社 有機ｅｌ素子およびジベンゾホスホールオキシド誘導体
WO2011125911A1 (ja) * 2010-03-31 2011-10-13 国立大学法人金沢大学 金属錯体およびこれを有効成分として含有する抗がん剤
US9326991B2 (en) 2012-09-14 2016-05-03 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds and use

Also Published As

Publication number Publication date
CN104974187A (zh) 2015-10-14
EA201692045A1 (ru) 2017-05-31
EP3130593B1 (en) 2020-09-23
CN106661060A (zh) 2017-05-10
EA030709B1 (ru) 2018-09-28
CA2944805C (en) 2022-11-29
EP3130593A1 (en) 2017-02-15
KR20160146791A (ko) 2016-12-21
EP3130593A4 (en) 2017-11-01
US10072035B2 (en) 2018-09-11
CA2944805A1 (en) 2015-10-15
CN106661060B (zh) 2019-04-19
SG11201608422VA (en) 2016-11-29
US20170029452A1 (en) 2017-02-02
KR102369908B1 (ko) 2022-03-02
JP2017513934A (ja) 2017-06-01
WO2015154716A1 (zh) 2015-10-15

Similar Documents

Publication Publication Date Title
RU2160257C2 (ru) Способ получения фенильных гетероциклов и промежуточное соединение
TWI324066B (en) A pharmaceutical composition for inhibiting cell migration induced by an angiogenic factor
CN104447867A (zh) 一种噻吩并哌啶衍生物、制备方法及其应用
WO2016138026A1 (en) Gemcitabine derivatives
JP6545254B2 (ja) リン含有フェナントロリン誘導体及びその調製方法と応用
JPWO1999011640A1 (ja) エポキシコハク酸アミド誘導体
JP2023538638A (ja) ピラゾールボロン酸化合物、それを含有する医薬組成物、及びそれらの使用
JP2017513934A5 (enExample)
WO2019119832A1 (zh) 用于代谢性疾病治疗的化合物及其制备方法和应用
KR102636651B1 (ko) 티아졸로피리딘 또는 이의 약학적으로 허용 가능한 염 및 이의 용도
CN103370102A (zh) 作为鞘氨醇1-磷酸(s1p)受体调节的新型肟衍生物
CN107245074A (zh) 用于治疗脑梗死的化合物及其制备方法
CN115141169B (zh) 一种萜内酯衍生物及其在医药上的应用
TW202116329A (zh) 環狀去氧核糖核苷酸化合物
CN105801646B (zh) 炔基取代的核苷氨基磷酸酯
RS53896B1 (sr) Pantenil dokosaheksaenoat i njegova upotreba za lečenje i prevenciju kardiovaskularnih oboljenja
TWI424843B (zh) 新穎組胺酸衍生物
HK1231883A1 (en) Phenanthroline phosphonic acid derivative and preparation method therefor and application thereof
HK1231883B (zh) 菲罗啉膦酸类衍生物及其制备方法和应用
CN116685573B (zh) 含有n-(取代磺酰基)乙酰胺结构的病毒蛋白酶抑制剂，及其在抗病毒药物中的应用
JP6850911B2 (ja) ビニルアレーン誘導体およびその使用
CN107823208A (zh) 吗啉类化合物在制备治疗和预防肾纤维化药物中的应用
CN102459269B (zh) 嘌呤衍生物以及使用所述嘌呤衍生物的抗肿瘤剂
CN120943801A (zh) 一种具有取代二苯醚结构的小分子化合物及其制备和应用
RU2024137255A (ru) Новые производные индазола

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180315

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20181019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20181019

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190521

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190618

R150 Certificate of patent or registration of utility model

Ref document number: 6545254

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250